VBWG at ACC 2018 Prof. Gomberg-Maitland gives numerous reasons why cardiologist should be interested in PAH, including updated knowledge on genetics and pathophysiology and interestingly, novel targets for therapy and different therapy strategies.

VBWG at ACC 2018 After lack of sham-controlled trials, the SPYRAL program has started to test the efficacy of renal denervation in patients with uncontrolled hypertension. Two pilot studies with a sham controlled group in patients without and with medications are nearly finished.

VBWG at ACC 2018 Several novel targets have been discovered and new lipid-modifying therapies are being developed to prevent CVD, beyond LDL-c. Elliot Brinton discusses several of these, including omega-3 prescriptions, pemafibrate, apoC3, Lp(a), and shares the first trial results.

VBWG at ACC 2018 In a debate about muscle symptoms in patients on statins, Thompson defended the statement that these symptoms are real by discussing the results of several clinical trials and studies examining the biochemical mechanism.

VBWG at ACC 2018 William Boden emphasizes the importance of using a sham control in clinical trials testing the effectivity of PCI and elaborates on this in respect to the ORBITA trial evaluating PCI treatment in patients with stable angina.

ACC 2018 The MOMENTUM 3 study results show a large reduction in stroke and need for reoperation, as no pump thrombosis occurred, with the new Heartmate 3 device, in comparison with the Heartmate 2.

Peter Libby shares a new finding that may explain how the major clinical problems in contemporary clinics, namely aging, cancer and CV disease, are linked, through processes independent of traditional CV risk factors.

ACC 2018 Steven Nissen compares ODYSSEY OUTCOMES with FOURIER and concludes that the results of these 2 studies in 2 different patient populations reinforce our understanding of the benefit of reducing LDL-c levels in patients with moderate LDL-c levels.

ACC 2018 Prof. Ray considers current insights on the class of PCSK9 inhibiting monoclonal antibodies, and he looks ahead at another PCSK9 inhibiting agent.

ACC 2018 Prof. Connolly summarizes the results of the interim analysis of the ANNEXA-4 trial: andexanet was effective in the reversal of the effect of FXa inhibitors and reversed FXa-associated bleedings in patients with acute major bleedings.

ACC 2018 Results of the SECURE-PCI trial showed a 28% decrease of MACE in patients treated with avorstatin compared to placebo before PCI intervention after ACS.

ACC 2018 In patients post-STEMI, treatment with ticagrelor resulted in similar rate of TIMI-bleedings as clopidogrel after 30 days in the TREAT trial.